Dendreon Corp. DNDN Stock Halted FDA Approval

Shares of Dendreon Corp. (DNDN) have been halted and the company just announced they have received FDA Approval for Provenge.

FDA clears Dendreon's prostate cancer vaccine.

Before the stock halt, Dendreon's stock traded above $45 per share. When DNDN reopens for trading this afternoon, I expect shares to trade between $50-$60.


Today's Biggest Stock Market Gainers - Top 2010 Stock Gainers - Top 2010 Penny Stocks - Top 2009 Stock Gainers - Top 2009 Penny Stocks - Hot OTC Stocks - Stocks for 2010

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Biggest Stock Gainers 4/29/09 April 29, 2009

Today, April 29, 2009, there are several stock gainers that are breaking out with some nice momentum. If you are looking to day trade today, you might want to check out the following stocks. Check out today's biggest gainers and the Top Stocks for 2009. You can find yesterday's Top Gainers Report Right Here

Top Stocks 4/29/09 - Biggest Gainers Today

Discuss - http://stockstobuy.org

Dendreon Corp. (DNDN) - $23.18 Up 95.26% - Brokers upgrade Dendreon on cancer vaccine

Wyndham Worldwide Corporation (WYN) - $11.87 Up 35.50% - Wyndham Worldwide posts profit on cost cuts

SAVVIS Inc. (SVVS) - $12.22 Up 36.08% - Savvis Reports First Quarter 2009 Results

Psychiatric Solutions, Inc. (PSYS) - $18.27 Up 27.32% - Psychiatric Solutions Q1 profit tops market estimate

Ameristar Casinos Inc. (ASCA) - $18.94 Up 26.77% - Ameristar tops view, restarts dividend,shares soar

DreamWorks Animation SKG Inc. (DWA) - $22.85 Up 19.93% - DreamWorks posts higher 1st-quarter net, shares up

Massey Energy Co. (MEE) - $14.98 Up 19.63% - Coal miner Massey's Q1 flat, revenue jumps

Life Technologies Corporation (LIFE) - $36.94 Up 15.30% - Life Tech profit tops Street view, shares rise

Other Stock Gainers:

ATC Technology Corporation. (ATAC)
Prestige Brands Holdings Inc. (PBH)
Wright Express Corp. (WXS)
Chicago Bridge & Iron Company N.V. (CBI)
Meredith Corp. (MDP)
Phase Forward Inc. (PFWD)

Today's Biggest Stock Market Gainers - Top 2009 Stock Gainers - Top 2009 Penny Stocks

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Biggest Stock Gainers 4/28/09 April 28, 2009

Today, April 28, 2009, there are several stock gainers that are breaking out with some nice momentum. If you are looking to day trade today, you might want to check out the following stocks. Check out today's biggest gainers and the Top Stocks for 2009. You can find yesterday's Top Gainers Report Right Here

Top Stocks 4/28/09 - Biggest Gainers Today

e-Future Information Technology Inc. (EFUT) - $11.34 Up 35.03% - eFuture Announces Fourth Quarter And Fiscal Year 2008 Unaudited Financial Results

Dendreon Corp. (DNDN) - $23.96 Up 11.04% - Dendreon's Provenge: Moment of Truth - Discuss DNDN

Office Depot, Inc. (ODP) - $3.06 Up 21.34% - Office Depot swings to loss on weak computer demand

Other Stock Gainers:

Mindspeed Technologies Inc. (MSPD)
Parexel International Corp. (PRXL)
Aaron's, Inc. (AAN)
Waters Corp. (WAT)
Virtual Radiologic Corporation (VRAD)
The Talbots Inc. (TLB)
ev3, Inc. (EVVV)
Novavax, Inc. (NVAX)
Meritage Homes Corporation (MTH)
Under Armour, Inc. (UA)

Top Stock Chat - Message Board

Today's Biggest Stock Market Gainers - Top 2009 Stock Gainers - Top 2009 Penny Stocks

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Dendreon DNDN Halted - News Pending 4/14/09

Dendreon ( DNDN ) shares are halted tonight, this happened right before 5pm Est. This is a T1 halt which means News Pending.

I will have an update when the news hits! I'm sure this has something to do with their Cancer Drug Provenge.

Update: 5:55pm EST

Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial

Dendreon Corporation (Nasdaq: DNDN) will host a conference call tomorrow, Tuesday, April 14, 2009, at 9:00 AM ET (6:00 AM PT) to review the outcome of the FINAL analysis of its IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer.

http://investor.dendreon.com/ReleaseDetail.cfm?ReleaseID=376909&Header=News

DNDN Stock will most likely remain halted until the news hits tomorrow. This stock is either headed to $10-$15 or $2 in my opinion. We'll See!

Update 4/14/09: Looks like Provenge data was positive, stock could open at $15-$20

http://finance.yahoo.com/news/Dendreon-cancer-drug-meets-apf-14918879.html

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Dendreon DNDN Stock April 13 2009 4/13/09

Shares of Dendreon ( DNDN ) are soaring in pre market trading this morning hitting $9.00 at one point on no news. Well, I assume news was leaked because I cannot find DNDN news anywhere. What I think is happening is news has been confirmed that Dendreon will release data at the American Urological Association (AUA) conference at the end of the month. I'm sure some kind of news will be released later in the day stating this.

Click Here for my previous article on DNDN

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Dendreon DNDN Stock April 3 2009 4/3/09

Dendreon DNDN stock just ripped higher in the past hour and was really lighting up my screen with big buy orders. Not sure if there is some kind of news leak or if this is just one of those classic short squeezes we have been seeing all across the Stock Market lately.

Update: Provenge Receives " Late Breaking Status " - CNBC reports at 3PM EST

Massive Volume! DNDN stock went from $4.40 - $6.60 in about 30 minutes with a 4 million surge in volume.

DNDN Option trading has been bullish over the past Three days. Traders are betting that any day this month Dendreon will release positive clinical data and submit an application to receive FDA approval on their Cancer Drug Provenge.

Here are two great articles from Forbes:

Dendreon Closing In On Provenge Profits - The biotech firm gets closer to its drug hitting the market.

Dendreon Disclosure May Endanger Provenge Study - A decision to trumpet results from an unfinished study could come back to bite the drug maker.

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Dendreon ( DNDN ) Provenge Study

Markets are tanking....but Dendreon DNDN shares are up 33% today because the company says they will release their final study on Provenge in about 8 months.

Dendreon Corp. (DNDN) said an interim analysis of a late-stage study shows its Provenge prostate-cancer therapy shows a 20% death-risk reduction compared to placebo.
President and Chief Executive Mitchell H. Gold said the findings, similar to those seen in prior phase 3 trials, should be finalized in mid-2009.

The study was ordered in May 2007 after the Food and Drug Administration requested more data to support the drug's proposed efficacy claim. An FDA advisory panel had voted Provenge had proven itself safe and effective.

Dendreon has been looking to get Provenge approved as a treatment for asymptomatic men with advanced prostate cancer who have stopped responding to hormone treatment. The drug is a departure from other approved cancer therapies in that it acts by stimulating the body's immune system to fight cancer using the patient's own white blood cells.

http://blackberrystocks.com/hotstocks.html